Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2…